摘要
目的探讨糖尿病性肾病性黄斑水肿行玻璃体内注射雷珠单抗联合后部眼球筋膜下注射曲安奈德的治疗效果方法回顾性分析郑州市第七人民医院2016年6月至2020年6月糖尿病性肾病性黄斑水肿60例(60眼)的临床资料。所有病例分为雷珠单抗组及雷珠单抗联合曲安奈德组,各30例(30眼)。分别行0.05ml雷珠单抗玻璃体内注射及雷珠单抗联合40 mg/0.5 ml曲安奈德后部眼球筋膜下注射。随访观察6个月结果注射后1周、1、3及6个月,两组患眼的视力及黄斑中心区厚度均较注射前明显改善(均P<0.05)。各随访时间点联合组视力均优于雷珠单抗组(t=2.826、2.964、3.028、2.626,P=0.024、0.012,0.012、0.026),黄斑中心区视网膜厚度降低更多(t=2.562、2.736、2.926、3.078,P=0.016、0.015、0.014、0.010)。结论玻璃体内注射雷珠单抗联合后部眼球筋膜下注射曲安奈德可以更有效地减轻糖尿病性肾病性黄斑水肿并改善视力。
Objective To investigate the efficacy of intravitreal injection of ranibizumab and posterior subtenon5 s injection of triamcinolone acetonide in the treatment of maclar edema due to diabetic nephropathy.Methods The clinical data of 60 eyes of 60 cases with macular edema due to diabetic nephropathy from Jun.2016 to Jun.2020 in the Seventh People's Hospital of Zhengzhou were retrospectively analyzed.All cases were divided into two groups,the ranibizumab group and the combined group,30 eyes of 30 cases in each group.The ranibizumab group received intravitreal injection of 0.05 ml ranibizumab,and the combined group received intravitreal injection of 0.05 ml ranibizumab combined with posterior subtenon5 s injection of 40 mg/0.5 ml triamcinolone acetonide.The follow-up time was 6 months.Results At 1 week,1,3 and 6 months after injection,the visual acuity and central macular thickness in both groups were significantly improved compared with that before injection,and the differences were statistically significant(all P<0.05).In addition,the visual acuity of the ranibizumab combined with triamcinolone acetonide group was better at each follow-up time point than that of the ranibizumab group(t=2.826,2.964,3.028,2.626;P=0.024,0.012,0.012,0.026),and the central macular thickness decreased more(t=2.562,2.736、2.926,3.078;P=0.016,0.015,0.014,0.010).Conclusion Intravitreal injection of ranibizumab combined with posterior subfascial injection of triamcinolone acetonide can more effectively alleviate macular edema clue to diabetic nephropathy and improve visual acuity.
作者
关微
张金嵩
刘德成
Guan Wei;Zhang Jinsong;Liu Decheng(Department of Ophthalmology,The Seventh People’s Hospital of Zhengzhou,Zhengzhou 450016,China;Department of Ophthalmology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《中华眼外伤职业眼病杂志》
2022年第1期64-70,共7页
Chinese Journal of Ocular Trauma and Occupational Eye Disease
关键词
水肿
黄斑
肾病性
糖尿病性
雷珠单抗
注射
玻璃体内
曲安奈德
注射
眼球筋膜下
后部
Edema,macular,nephropathy,diabetic
Ranihizumab,injection,intravitreal
Triamcinolone acetonicle,injection,subfascial,posterior
